Sponsor Dossier
Johnson & Johnson
Sponsor Dossier for Johnson & Johnson. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AGAROL
- Brand: Allergy
- Brand: BANLICE
- Brand: BENADRYL
- Brand: BUDAMAX AQUEOUS NASAL SPRAY
- Brand: Codral
- Brand: COMBANTRIN
- Brand: COMBANTRIN-1
- Device (sponsor): Adhesive strip, skin-cover
- Device (sponsor): Adhesive bandage
- Device (sponsor): Adhesive strip, skin-cover
- Device (sponsor): Exudate-absorbent dressing, hydrophilic-gel
- Device (sponsor): Adhesive tape, <specify>
- Device (sponsor): Dressing, compression
- Device (sponsor): Corn dressing
- Device (sponsor): Wound hydrogel dressing, sterile
- Device (sponsor): Adhesive bandage
- Device (sponsor): Bandage, adhesive
- Device (sponsor): Bandage, adhesive
About
Johnson & Johnson Pacific Pty Ltd is an Australian Private Company with ABN 73001121446, registered in NSW. The company is active and operates under several trading names including Aveeno, BAND-AID, Codral, and Listerine.
Portfolio
Johnson & Johnson has 29 brands on the ARTG, of which 6 are indexable and 3 carry a Product Information document. 4 brands are PBS-listed, 2 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include AGAROL, Allergy, BANLICE, BENADRYL, BUDAMAX AQUEOUS NASAL SPRAY, Codral, COMBANTRIN, COMBANTRIN-1, DAKTAGOLD, DAKTARIN, DAKTOZIN, GAMOPHEN.
Therapeutic focus
— Dermatology: 8 brands — Respiratory: 6 brands — Gastroenterology: 5 brands — Infectious Disease: 3 brands — Ophthalmology: 2 brands — Pain Management: 2 brands — Other: 1 brand — Psychiatry: 1 brand — Immunology: 1 brand
PBS footprint
4 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2019-03-01, across 2 brands with a PBAC outcome on record.